GH Quote, Financials, Valuation and Earnings

Quest Diagnostics, Inc. has a net margin of -34.97% compared to Guardant Health, Inc.'s net margin of 9.13%. Guardant Health, Inc.'s return on equity of -8518.58% beat Quest Diagnostics, Inc.'s return on equity of 14.33%.

Guardant Health, Inc. has a consensus price target of $114.05, signalling upside risk potential of 11.4%. On the other hand Quest Diagnostics, Inc. has an analysts' consensus of $198.06 which suggests that it could grow by 12.59%. Given that Quest Diagnostics, Inc. has higher upside potential than Guardant Health, Inc., analysts believe Quest Diagnostics, Inc. is more attractive than Guardant Health, Inc..

Guardant Health, Inc. has a beta of 1.579, which suggesting that the stock is 57.876% more volatile than S&P 500. In comparison Quest Diagnostics, Inc. has a beta of 0.618, suggesting its less volatile than the S&P 500 by 38.214%.

Guardant Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics, Inc. offers a yield of 1.79% to investors and pays a quarterly dividend of $0.80 per share. Guardant Health, Inc. pays -- of its earnings as a dividend. Quest Diagnostics, Inc. pays out 39.15% of its earnings as a dividend. Quest Diagnostics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Guardant Health, Inc. quarterly revenues are $265.2M, which are smaller than Quest Diagnostics, Inc. quarterly revenues of $2.8B. Guardant Health, Inc.'s net income of -$92.7M is lower than Quest Diagnostics, Inc.'s net income of $257M. Notably, Guardant Health, Inc.'s price-to-earnings ratio is -- while Quest Diagnostics, Inc.'s PE ratio is 20.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health, Inc. is 14.08x versus 1.83x for Quest Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

EXACT Sciences Corp. has a net margin of -34.97% compared to Guardant Health, Inc.'s net margin of -2.3%. Guardant Health, Inc.'s return on equity of -8518.58% beat EXACT Sciences Corp.'s return on equity of -38%.

Guardant Health, Inc. has a consensus price target of $114.05, signalling upside risk potential of 11.4%. On the other hand EXACT Sciences Corp. has an analysts' consensus of $104.56 which suggests that it could grow by 2.98%. Given that Guardant Health, Inc. has higher upside potential than EXACT Sciences Corp., analysts believe Guardant Health, Inc. is more attractive than EXACT Sciences Corp..

Guardant Health, Inc. has a beta of 1.579, which suggesting that the stock is 57.876% more volatile than S&P 500. In comparison EXACT Sciences Corp. has a beta of 1.417, suggesting its more volatile than the S&P 500 by 41.664%.

Guardant Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. EXACT Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health, Inc. pays -- of its earnings as a dividend. EXACT Sciences Corp. pays out -- of its earnings as a dividend.

Guardant Health, Inc. quarterly revenues are $265.2M, which are smaller than EXACT Sciences Corp. quarterly revenues of $850.7M. Guardant Health, Inc.'s net income of -$92.7M is lower than EXACT Sciences Corp.'s net income of -$19.6M. Notably, Guardant Health, Inc.'s price-to-earnings ratio is -- while EXACT Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health, Inc. is 14.08x versus 6.18x for EXACT Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Illumina, Inc. has a net margin of -34.97% compared to Guardant Health, Inc.'s net margin of 13.85%. Guardant Health, Inc.'s return on equity of -8518.58% beat Illumina, Inc.'s return on equity of 30.55%.

Guardant Health, Inc. has a consensus price target of $114.05, signalling upside risk potential of 11.4%. On the other hand Illumina, Inc. has an analysts' consensus of $125.28 which suggests that it could fall by -7.42%. Given that Guardant Health, Inc. has higher upside potential than Illumina, Inc., analysts believe Guardant Health, Inc. is more attractive than Illumina, Inc..

Guardant Health, Inc. has a beta of 1.579, which suggesting that the stock is 57.876% more volatile than S&P 500. In comparison Illumina, Inc. has a beta of 1.438, suggesting its more volatile than the S&P 500 by 43.845%.

Guardant Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Illumina, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health, Inc. pays -- of its earnings as a dividend. Illumina, Inc. pays out -- of its earnings as a dividend.

Guardant Health, Inc. quarterly revenues are $265.2M, which are smaller than Illumina, Inc. quarterly revenues of $1.1B. Guardant Health, Inc.'s net income of -$92.7M is lower than Illumina, Inc.'s net income of $150M. Notably, Guardant Health, Inc.'s price-to-earnings ratio is -- while Illumina, Inc.'s PE ratio is 30.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health, Inc. is 14.08x versus 4.97x for Illumina, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Natera, Inc. has a net margin of -34.97% compared to Guardant Health, Inc.'s net margin of -14.78%. Guardant Health, Inc.'s return on equity of -8518.58% beat Natera, Inc.'s return on equity of -26.6%.

Guardant Health, Inc. has a consensus price target of $114.05, signalling upside risk potential of 11.4%. On the other hand Natera, Inc. has an analysts' consensus of $246.26 which suggests that it could grow by 4.55%. Given that Guardant Health, Inc. has higher upside potential than Natera, Inc., analysts believe Guardant Health, Inc. is more attractive than Natera, Inc..

Guardant Health, Inc. has a beta of 1.579, which suggesting that the stock is 57.876% more volatile than S&P 500. In comparison Natera, Inc. has a beta of 1.628, suggesting its more volatile than the S&P 500 by 62.801%.

Guardant Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Guardant Health, Inc. pays -- of its earnings as a dividend. Natera, Inc. pays out -- of its earnings as a dividend.

Guardant Health, Inc. quarterly revenues are $265.2M, which are smaller than Natera, Inc. quarterly revenues of $592.2M. Guardant Health, Inc.'s net income of -$92.7M is lower than Natera, Inc.'s net income of -$87.5M. Notably, Guardant Health, Inc.'s price-to-earnings ratio is -- while Natera, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Guardant Health, Inc. is 14.08x versus 15.01x for Natera, Inc.. Usually stocks with elevated PS ratios are considered overvalued.